Chronic Active B Cell Receptor Signaling in Diffuse Large B Cell Lymphoma
By R. Davis, Vu N. Ngo, G. Lenz, P. Tolar, R. Young, Paul B. Romesser, H. Kohlhammer, L. Lamy, Hong Zhao, Yandan Yang and 27 more. Nature, 2010
1,639 citations recorded by the source corpus.
A role for B-cell-receptor (BCR) signalling in lymphomagenesis has been inferred by studying immunoglobulin genes in human lymphomas and by engineering mouse models, but genetic and functional evidence for its oncogenic role in human lymphomas is needed. Here we describe a form of ‘chronic active’ BCR signalling that is required for cell survival in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL). The signalling adaptor CARD11 is required for constitutive NF-κB pathway activity and survival in ABC DLBCL. Roughly 10% of ABC DLBCLs have mutant CARD11 isoforms that activate NF-κB, but the mechanism that engages wild-type CARD11 in other ABC DLBCLs was unknown. An RNA interference genetic screen revealed that a BCR signalling component, Bruton’s tyrosine kinase, is essential for the survival of ABC DLBCLs with wild-type CARD11. In addition, knockdown of proximal BCR subunits (IgM, Ig-κ, CD79A and CD79B) killed ABC DLBCLs with wild-type CARD11 but not other lymphomas. The BCRs in these ABC DLBCLs formed prominent clusters in the plasma membrane with low diffusion, similarly to BCRs in antigen-stimulated normal B cells. Somatic mutations affecting the immunoreceptor tyrosine-based activation motif (ITAM) signalling modules of CD79B and CD79A were detected frequently in ABC DLBCL biopsy samples but rarely in other DLBCLs and never in Burkitt’s lymphoma or mucosa-associated lymphoid tissue lymphoma. In 18% of ABC DLBCLs, one functionally critical residue of CD79B, the first ITAM tyrosine, was mutated. These mutations increased surface BCR expression and attenuated Lyn kinase, a feedback inhibitor of BCR signalling. These findings establish chronic active BCR signalling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.
Subfields: Immunology, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/1482c187c368ba579e04023c68f6713fc405a00e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
In Pathology and Forensic Medicine
Citations in the corpus
- Inactivating mutations of acetyltransferase genes in B-cell lymphoma (2011, background): “CREBBP and EP300 enhance transcription by multiple mechanisms, including: (1) targeted acetylation of chromatin(12,13); (2) acetylation of transcriptional activators (such as the tumour suppressors p53 and GATA1); and (3) acetylation-mediated inactivation of transcriptional repressors (such as the D”
- Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. (2011, background): “Moreover, the murine lung carcinomas that respond to NF-kB inhibition have bypassed senescence through mutant p53 (Meylan et al. 2009; Feldser et al. 2010).”
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy (2010, background): “Validation of this probe in dogs with spontaneous NHL and the agreement between Btk occupancy in PBMC and tumor biopsies supports the current use of PCI-33380 as a pharmacodynamic marker in PBMCs in ongoing human clinical trials.”
- Targeted protein degradation: mechanisms, strategies and application (2022, background): “BTK, a tyrosine kinase and a key regulator of the BCR (B-cell receptor) pathway, is up-regulated in a variety of lymphoma cells.(72) GSPT1, a translation termination factor, is involved in regulation of mammalian cell growth.”
- NF-κB in biology and targeted therapy: new insights and translational implications (2024, background): “104,105 Recent fi ndings have revealed that PI3K activates NF-κ B signaling through the cIAP-IKK pathway, and copanlisib, a dual inhibitor of PI3K α / δ , may effectively block PI3K/AKT signaling and NF-κ B signaling in ABC-DLBCL, leading to tumor regression.”
- Role of Bruton’s tyrosine kinase in B cells and malignancies (2018, background): “In addition, recurrent mutations in the TLR/NF-κB pathway were found, affecting e.g. the MYD88, TRAF3, CARD11, A20/TNFAIP3 and CARD11 genes [183].”
- Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. (2013, background): “selectively cytotoxic to DLBCL cell lines driven by chronic active BCR signaling.(17) Orally administered ibrutinib resulted in objective clinical responses in dogs that spontaneously developed non-Hodgkin lymphoma (NHL).”